The Estée Lauder group introduced on Thursday, April 30, a minority funding in 111SKIN, a luxurious scientific skincare model based in 2012 by plastic and reconstructive surgeon Dr. Yannis Alexandrides and his spouse Eva. Phrases of the funding weren’t disclosed.
Initially developed to speed up post-procedure therapeutic, 111SKIN harnesses a proprietary advanced — NAC Y2 — designed to help pores and skin restore whereas selling a wholesome, radiant, and resilient complexion.
The model has developed a portfolio of greater than 30 merchandise, priced from USD 50 to USD 1,000. 111SKIN operates in a fast-growing phase the place medical experience and highly effective high-performance formulations meet.
“Skincare is coming into a brand new section, formed by the convergence of procedures, longevity and wonder, as shoppers more and more search merchandise that ship seen, treatment-inspired outcomes,” stated Stéphane de La Faverie, President and Chief Government Officer, The Estée Lauder Firms. “111SKIN exemplifies this shift, translating Dr. Alexandrides’ greater than 35 years of surgical and aesthetic remedy expertise into high-performance luxurious skincare impressed by in-clinic therapies and constructed on scientific perception, next-generation actives, highly effective formulation and confirmed efficacy.”
111SKIN distributes by way of luxurious retail, e-commerce and high-end spa channels – together with Harrods, Bluemercury, Nordstrom, Mandarin Oriental, and Aman – and has a strong direct-to-consumer enterprise representing roughly 20% of gross sales, reflecting robust digital engagement with status shoppers.
The model has a diversified world footprint, with North America representing roughly 40% of 2025 gross sales, and a longtime presence throughout China, the UK, Europe and Asia Pacific.
Dr. Alexandrides will stay actively concerned within the model and can proceed to steer 111SKIN alongside its skilled administration group, together with CEO Vanessa Goddevrind.
